Skip to main content

RUCONEST® is an orphan drug designated therapy developed by Pharming, already approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in the US and EU. This transaction will accelerate Pharming’s development into a profitable specialty pharmaceutical company with its own independent commercial infrastructure, which will form the foundation for future growth.

“This is a quantum leap forward for Pharming and marks a significant step for the Company taking control of its own destiny and providing a real prospect of reaching profitability soon."

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline